Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer
18 juil. 2019 10h40 HE
|
Rafael Pharmaceutical Inc.
Cranbury, NJ, July 18, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the...
Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) in Japan and Other Asian Countries
25 juin 2019 08h00 HE
|
Rafael Pharmaceutical Inc.
Cranbury, NJ, June 25, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that...
Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, Named Finalist for The 2019 EY Entrepreneur Of The Year® Award in New Jersey
06 juin 2019 08h00 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, June 06, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, has announced that...
Rafael Pharmaceuticals to Present at the 2019 Jefferies Global Healthcare Conference
04 juin 2019 08h00 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, June 04, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, will present at the...
Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, to be Honored by American Cancer Society at Annual Starry Night Gala
16 mai 2019 13h05 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, May 16, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that...
Rafael Pharmaceuticals Appoints Senior Vice President for Clinical Development and Operations
13 mai 2019 08h00 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, May 13, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the...
Devimistat (CPI-613®) to be Explored in a New Combination for T-Cell Lymphoma Treatment as Part of Stand Up To Cancer’s T-Cell Lymphoma “Dream Team Research Grant”
07 févr. 2019 08h55 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...
Rafael Pharmaceuticals to Present Plan for Phase 3 Trial (AVENGER 500) of devimistat (CPI-613®) in Combination with Modified FOLFIRINOX as a First Line Treatment for Metastatic Pancreatic Cancer at 2019 Gastrointestinal Cancers Symposium
17 janv. 2019 08h00 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the study plan for a Phase 3...
EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ devimistat (CPI-613®) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
10 janv. 2019 11h00 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the European Medicines Agency...
EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ devimistat (CPI-613®) for Treatment of Metastatic Pancreatic Cancer
10 janv. 2019 08h00 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the European Medicines Agency...